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ABSTRACT 
Demography, Clinical Features, Etiology, Management and Outcomes in 
Acute Retinal Necrosis: A Prospective Study. 
INTRODUCTION: A prospective study of demography, clinical features, etiology, 
management and outcomes in Acute retinal necrosis(ARN) 
METHODS: Prospective, observational, hospital based case series study of ARN 
patients reported for 1year and a follow up period of six months. Demographic 
profile, immune status of the patients recruited was recorded. Relevant history, 
initial visual acuity, clinical feature documented. Patient was diagnosed to have 
ARN if had feature as suggested by standard diagnostic criteria proposed by 
American uveitis society. Few patients underwent vitreous tap for viral DNA 
analysis through PCR. Patients are treated with oral antiviral as sole antiviral or 
combined antiviral therapy with intravenous, intravitreal and orally along with 
corticosteroids and cycloplegics. Occurrence Complication like retinal detachment, 
secondary glaucoma and fellow eye involvement was documented. Management of 
complication was also documented. Final visual acuity at the end of six month 
follow up period was noted. 
RESULTS: This study enrolled total of 29 patients and 31 eyes. Out of the 29 
patients 1 patient died during the follow up period and 1 patient lost follow up. 
Therefore for end point observations results are calculated with 27 patients and 29 
eyes. Minimum age of presentation was 18 years and maximum was 65 years. 
Mean age was 42.1 years. Totally 5 patients out of 29 patient are 
immunocompromised. Previous history of viral infection was given by 6 patients 
(20.7%). The most common viral infection being chicken pox seen 3 patients 
(50%). Most common symptom found was defective vision (100%). The mean 
clock hours of retinal necrosis observed was 5.12 clock hours. Vitreous sample of 
11 patients was analyzed for herpes family virus through polymerase chain 
reaction, Varizella zoster was detected in 2 patients (18.18%) and in 9 patients no 
organism could be detected. Out of total 31 eyes, 17 eyes(55%) treated with sole 
oral antiviral and 14 eyes (45%) treated with combined antiviral therapy. , 34.4% 
(10 eyes) suffered retinal detachment. Mean time gap of occurrence of retinal 
detachment was found to be 4.2 weeks. Occurrence of retinal detachment in 
combined therapy 69.3% (9 eyes out of 16 eyes) and in oral antiviral therapy group 
was 6.25% ( 1 out of 16 eyes). There exist a statistical significance (P= 0.001) in 
occurrence of retinal detachment between oral therapy group and combined 
antiviral group. Re retinal detachment occurred in 28.6% eyes ( 2 eyes) on silicon 
oil removal. 10% progressed to secondary glaucoma. 2 patients out 29 had fellow 
eye involvement, with mean time gap of involvement being 2.5 weeks. The over all 
mean initial acuity in 31 eyes was 0.96LogMar±0.70 (1SD), mean final visual 
acuity in 29 eyes was 0.69LogMar±0.60 (1SD). On analysis if was found there 
exist a statistically significant (P=0.002) improvement in vision at the end of six 
months of treatment. The mean initial visual acuity in oral antiviral therapy group 
was 0.79LogMAR±0.57 (1SD) and mean final visual acuity was 0.46±0.26 
LogMar. A statistically significant (P=0.006) improvement in visual acuity between 
initial and final vision in oral therapy.  No statistical significant (P=0.183)  
improvement in visual acuity was noted between initial (mean= 1.16LogMar±0.81 
(1SD)) and final visual acuity ( mean 0.99±0.76 LogMar) in combined antiviral 
therapy group. There exists a statistical significant difference (P=0.026) between 
final vision between oral antiviral and combined antiviral group with oral antiviral 
therapy group had better final visual acuity. 
CONCLUSION: Acute retinal necrosis is rare but potential blinding disease, 
polymerase chain reaction on ocular fluids helps to identify viral DNA and 
appropriate treatment can be instituted. Oral antiviral and intravitreal antiviral are 
increasingly used in treatment of ARN. Primary treatment with oral antiviral for 
indolent ARN is an effective alternate to combined therapy as the later is invasive 
and requires hospitalization. Prompt diagnosis and good therapeutic approach is a 
must for better visual recovery. Vision threatening complication like retinal 
detachment can be prevented with judicious monitoring of ARN patients and 
prompt treatment. Despite, advances in treatment and diagnostic modalities 
available like polymerase chain reaction (PCR) to identify virus with intraocular 
fluid, ARN continues to remain as an ophthalmological emergency with retinal 
lesion progressing rapidly after the disease onset. Precise understanding about this 
disease condition by ophthalmologist is at most important for prompt diagnosis and 
treatment. 
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